CD274 and neoplasm: Biomarker analyses using tumour tissues such as tumour mutational burden, microsatellite instability/mismatch repair deficiency, or PD-L1 scoring in tumour and immune cells [15] may provide a strong rationale to select eligible dogs that can be successfully treated with ICIs.